Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference
Get Alerts SLGL Hot Sheet
Join SI Premium – FREE
NESS ZIONA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will participate in the Cantor Global Healthcare Conference, taking place virtually from September 27th – 30th, 2021.
Cantor Global Healthcare Conference Presentation Information: | |
Format | Fireside chat discussion and 1-on-1 meetings |
Speaker: | Dr. Alon Seri-Levy, Chief Executive Officer and Mr. Gilad Mamlok, Chief Financial Officer |
Date: | Thursday, September 30th |
Time: | Discussion available on demand beginning Thursday, September 30th 10:40 a.m. ET (TRACK 3) |
To Listen | To listen to the discussion, click here. A replay will be archived for 30 days at this link (or go to www.sol-gel.com to access within the Investors/Events and Presentations section). |
About Sol-Gel Technologies
Sol-Gel is a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for TWYNEO, which is FDA approved for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, under investigation for the treatment of inflammatory lesions of rosacea with an NDA filed with the FDA and a PDUFA goal date that was set for April 26, 2021. Action on the NDA for EPSOLAY has not yet been taken due to the inability of the FDA to conduct a pre-approval inspection of the production site of EPSOLAY as a result of COVID-19 travel restrictions. Both product candidates are exclusively licensed for U.S. commercialization with Galderma.
The Company’s pipeline also includes early-stage topical drug candidates SGT-210 (erlotinib gel) under investigation for the treatment of palmoplantar keratoderma, SGT-310 (tapinarof cream, 1%) and SGT-510 (roflumilast) under investigation for the treatment of plaque psoriasis and other dermatologic indications.
For additional information, please visit www.sol-gel.com.
Contact:
Irina KofflerInvestor relations, LifeSci Advisors[email protected]+1-917-734-7387
Sol-Gel TechnologiesGilad MamlokChief Financial Officer[email protected]
Source: Sol-Gel Technologies Ltd.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- ALL KIDS BIKE® RECEIVES 2024 GRANT AWARD FROM YAMAHA’S OUTDOOR ACCESS INITIATIVE
- LEADING EDGE MATERIALS ANNOUNCES RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
PDUFA, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!